Will the launch of ‘Giotrif’ change the dynamics of the Korean cancer treatment market?
Intense attention has been focused on ‘Giotrif’ calling itself the irreversible ErbB Family Blocker.
Boehringer Ingelheim Korea held a press conference to celebrate the launch of insurance benefit for EGFR (Epidermal Growth Factor Receptor) mutation positive nonsmall-cell lung cancer treatment ‘...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
